In Florida, Abengoa Bioenergy New Technologies has agreed to pay Dyadic $5.5 million for an expansion of its rights under the non-exclusive license agreement the parties entered into in February 2009. The license agreement originally provided Abengoa with the right to use Dyadic’s C1 platform technology to develop, manufacture and sell enzymes for use in second generation biorefining processes to convert biomass into sugars for the production of fuels, chemicals and/or power in certain territories.
The amended license agreement expands the territories to worldwide rights and provides Abengoa with the ability to produce, use and sell C1 enzymes in first as well as second generation biofuels and other bio-based processes.
More background on the story from the Digest
Category: Producer News